Literature DB >> 7150337

Dichloroacetate tissue concentrations and its relationship to hypolactatemia and pyruvate dehydrogenase activation.

O B Evans.   

Abstract

Following a single oral dose of DCA to laboratory rats, peak hepatic tissue DCA concentration occurred at 3 hr. When given chronically for 7 days, DCA caused activation of the pyruvate dehydrogenase complex which returned to basal activity 24 hr following the final dose. Hepatic tissue DCA concentrations were maximally increased at 3 hr following the final dose, and the drug was eliminated slowly over 72 hr with a half-life of 9.74 hr. Liver and muscle showed similar DCA tissue concentrations following chronic administration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7150337     DOI: 10.1016/0006-2952(82)90092-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Treatment of chronic congenital lactic acidosis by oral administration of dichloroacetate.

Authors:  Y Kuroda; M Ito; K Toshima; E Takeda; E Naito; T J Hwang; T Hashimoto; M Miyao; M Masuda; K Yamashita
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

2.  Haemodialysis studies with dichloroacetate.

Authors:  S H Curry; A Lorenz; G N Henderson; D R Mars; P W Stacpoole
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Dichloroacetate, a pyruvate dehydrogenase kinase inhibitor, ameliorates type 2 diabetes via reduced gluconeogenesis.

Authors:  Yuko Katayama; Yayoi Kawata; Yusuke Moritoh; Masanori Watanabe
Journal:  Heliyon       Date:  2022-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.